Profund Advisors’s Stoke Therapeutics STOK Stock Holding History

Profund Advisors’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$733K	Sell	22,416 -4,569	-17%	-$147K	0.02%	427
2026 Q1	$879K	Sell	26,985 -6,403	-19%	-$210K	0.03%	382
2025 Q4	$1.06M	Buy	+33,388	New	+$1M	0.03%	344
2025 Q3	–	Sell	-10,986	Closed	-$125K	–	1089
2025 Q2	$125K	Sell	10,986 -1,896	-15%	-$18K	﹤0.01%	952
2025 Q1	$85.7K	Sell	12,882 -266	-2%	-$2.48K	﹤0.01%	965
2024 Q4	$145K	Sell	13,148 -3,253	-20%	-$40K	0.01%	1046
2024 Q3	$202K	Buy	16,401 +1,508	+10%	+$21.4K	0.01%	1049
2024 Q2	$201K	Buy	+14,893	New	+$201K	0.01%	989

Other funds holding STOK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Profund Advisors's STOK Position: Q2 2026 in Review

Profund Advisors reduced its Stoke Therapeutics (STOK) stake by 17% in Q2 2026, selling an estimated $147K and leaving 22,416 shares worth $733K. The position accounts for 0.02% of the portfolio, ranked #427.

Profund Advisors first reported a position in STOK in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.06M in Q4 2025. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

Profund Advisors held 22,416 shares of Stoke Therapeutics worth $733K as of Q2 2026.
Profund Advisors sold 4,569 Stoke Therapeutics shares in Q2 2026, an estimated $147K.
Stoke Therapeutics made up 0.02% of Profund Advisors's portfolio in Q2 2026, its #427 holding.
Profund Advisors first reported a position in Stoke Therapeutics in Q2 2024 and has held it in 8 quarters since.
Profund Advisors's Stoke Therapeutics position peaked at $1.06M in Q4 2025.
197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.